Here the link to our study examining the effect of first-line ablation vs AAD on AF progression.
Thanks to
@AHAScience
for welcoming me back to present the results, and to
@NEJM
for the simultaneous publication.
@CCI_CIC
@UBCDoM
@CHRS_SCR
@SCC_CCS
Last week I did zoom ECG teaching.
I thought I’d use this thread to share some of the more interesting ECGs I found while prepping.
Here’s the first - May not seem remarkable at first glance but I’ve never seen it before (though I have seen something similar).
The 2023 ACC/AHA guidelines have elevated the role of catheter ablation as the initial treatment of AF.
As a topic that has been near and dear to my heart for the past 10 or so years, it’s fantastic to see the field evolve towards offering more effective treatments earlier
Yesterday I had the privilege to present the results of the CIRCA-DOSE trial as part of the late breaking trials session at
#EHRA2019
. For those that missed it I thought I would recap the presentation in this thread.
@escardio
@VCHResearch
@HeartandStroke
@UBCDoM
Many thanks to the
@WhitecapsFC
for honouring me as the frontline hero of the match.
Knowing we have the support of our community is a wonderful feeling after the significant challenges over the last 20 months.
On behalf of my colleagues
@VCHhealthcare
&
@CCI_CIC
I’m honoured.
As immensely proud as I am for the entirety of the comprehensive 2020 CCS/CHRS atrial fibrillation guidelines...this sentence alone gives me immense joy.
1. Earlier in December I had the privilege to speak at the Cardiovascular Collaborative Medicine Conference in Manhattan on the role of catheter ablation post CABANA. I thought I'd present that talk via tweetorial. I'm not sure how well it will adapt to this form, but here goes..
1/ In October 2018 the
@SCC_CCS
released an update to the AF guidelines. This update included a significant revision of the recommendations for anticoagulation therapy around cardioversion. Space limited the discussion so...
ARTESIA results presented by Jeff Healey.
- significant 37% reduction in stroke/embolism with apixaban vs aspirin
- less severe and disabling strokes with apixaban
- roughly a doubling in major bleeding vs aspirin.
Yesterday we presented the 2020
@SCC_CCS
atrial fibrillation guidelines.
This comprehensive renewal is the result of two years of collaboration, involving 40 authors, 10 external reviewers, 6 societies, and esteemed patient partners (
@HeartLifeCanada
).
I was supposed to be in Amsterdam at ESC but COVID obviously altered those plans.
Instead we undertook a 2500 km road trip through western Canada.
Below are 4 photos demonstrating the varied landscape in Lake Louise and Drumheller AB, and Revelstoke and Penticton BC.
1. Today I presented the late breaking results of our clinical trial examining AF progression after catheter ablation.
This was a long-term follow up of the CIRCA-DOSE population, a group of 356 patients randomised to Contact force RF or Cryoballoon PVI
Interesting data out of Ontario Canada.
One in five patients waiting for AF ablation died, was hospitalized, or visited the emergency department for atrial fibrillation or heart failure.
Events 50% more for paroxysmal AF.
Mean wait time 244 days.
I had a recent case that I thought was a good example to initiate a discussion within our community.
Late 60s, OSA, Inflammatory arthritis, Elevated DR-FLASH Score.
Persistent AF
No history of cardiac intervention.
This was the baseline voltage map in sinus rhythm.
Ever wonder about the effectiveness of medical therapy for idiopathic frequent PVCs (>5%)?
- Beta-blockers and Calcium channel blockers are ineffective.
- Class I and III Antiarrhythmic drugs were more effective but suppressed PVCs (to <1%) in only 1/3
A new dedicated EP lab needs a new mapping solution. Thanks to the
@VGHFdn
we were able to acquire the first
@BSCCardiology
Rhythmia system in Western Canada. Lumipoint and DirectSense are interesting tools to add to our growing Heart Rhythm program.
@UBCDoM
@VCHResearch
I’m happy to announce CIRCA-DOSE has now been published in
@CircAHA
Again, many thanks to my collaborators, mentors, and colleagues.
This project began with an animal study as a fellow at
@ICMtl
and grew into a multicenter
@HeartandStroke
funded RCT.
Our recent review on asymptomatic AF - in it we discuss important management differences between asymptomatic AF and Subclinical/DDAF.
@MarcDeyell
@RBennett_EP
As someone who is today days old, I have not had a large study published in
@NEJM
So it’s absolutely amazing that young Thomas Khairy has a first author publication in
@NEJM
at 15!
Hearty congrats to my friends at
@ICMtl
and Marie-Andrée in particular
INVICTUS doesn’t change the current recommendations regarding valvular AF present in the
@SCC_CCS
@escardio
or
@AHAScience
AF guidelines.
But that’s why it is big news.
I expected it would.
Out with the old, and in with the new (EP lab).
Thanks to
@VGHFdn
, the division of cardiology at
@VCHhealthcare
, the project managers, and staff who helped us realise our goal of providing arrhythmia care to British Columbians in our new dedicated EP lab.
@adriandix
@Philips
Join us Monday am at
#AHA20
LBCT 6 when we will present the results from the EARLY-AF study.
303 patients randomised to cryoballoon vs AAD therapy as 1st line treatment.
All patients had a loop recorder.
Found this in my files while preparing for an upcoming talk. I feel like it summarises the discourse.
Most of science is iterative and inching towards truth. Uncertainty is the norm. The eureka moments are rare.
Science is process and progress.
@drjohnm
Interesting results from CASTLE-HTx
Will require a deeper dive but interesting that the survival curves differ so much from that observed in CASTLE, particularly since the populations aren’t that different.
Congrats to
@chris_sohns
et al
Our systematic review on atrial flutter and heart failure is available in
@ESC_Journals
In contrast to atrial fibrillation, there is little evidence looking at the implications of flutter on HF outcomes, nor dedicated trials to guide management decisions.
Commotio Cordis (cardiac arrest secondary to blunt, nonpenetrating trauma to the chest wall) usually occurs in younger men with more malleable & thinner chest walls. However it rarely occurs in those > 20, particularly with underlying cardiomyopathy
For those who were present at my debate with
@drjohnm
- the paper I referenced regarding the increasing safety of AF ablation is now available
In short / major complications have decreased over the last decade, highlighting our progress as a field
Please see our Stare of the Art review in
@JACCJournals
regarding the role of first line cryoballoon ablation versus AAD therapy.
We explore the effect if first-line ablation on arrhythmia recurrence, QOL, and healthcare utilisation.
@omwazni
@UBCDoM
Today the 2018
@SCC_CCS
atrial fibrillation guideline update was released.
This year we added several sections.
The first is a significant discussion on the role of cardiovascular risk factors on AF incidence and progression.
@PrashSanders
@DrScottLear
Our paper on autonomic alterations after pulmonary vein isolation is now available. Using the CIRCA-DOSE dataset we were able to perform an in-depth analysis of heart rate response and HRV pre- and post PVI.
@MDTolgaAksu
We recently performed the first pulsed field ablation procedures in Canada
A heartfelt thank you to
@VGHFdn
for their commitment to excellence and their dedication to our community's well-being. Together we are ensuring that quality healthcare is accessible to people living in BC
Happy to share the news that our recent AF screening study using
@AliveCor
Kardia devices in 334 primary care practices has been accepted at
@pace_journal
.
We found AF in 7% of screened patients, with >4% of screened patients newly starting OAC.
Our paper examining atrial fibrillation burden and Healthcare utilization/quality of life from the CIRCA-DOSE study is now available in the European Heart Journal
@CCI_CIC
@UBCDoM
@ICMtl
@VCHResearch
@HlthResearchBC
I’ve tweeted about this before, but happy to report our article on same day discharge in 2400 patients after AF ablation is now in print
Interesting in that it may take on a new perspective in the COVID era of trying to avoid prolonged hospitalisations
Super interesting study.
Key points to me
- things get worse while waiting for ablation but
- delaying ablation one does not cause harm at 1 year (in terms of post ablation recurrence).
Suggests to me that the current DAT (Dx-ablation-time) threshold of a year is reasonable
#EHRA2023
#LBCT
Jonathan Kalman
Impact of catheter ablation timing on arrhythmia outcomes
Early ablation (<1 mth)
vs
Delayed
#AFib
ablation (12 mths)
👉🏻 No difference in rhythm outcome…
Congrats to
@VivekReddyMD
and collaborators on the publication of the ADVENT randomised clinical trial.
It’s incredibly important that we continue to pursue comparative trials as we consider adopting new technologies into practice.
Considering the hours of work we put into our research, and manuscript preparations, and resubmissions, it is lovely to receive such kind words from the reviewer.
These small acts of kindness are simple but important.
It’s something I will now be incorporating into my reviews
I had a wonderful visit in Tokyo with Professor Yamane.
His accomplishments and knowledge speaks for itself, but more importantly he is a wonderful and kind man, who extended me the most wonderful hospitality.
I look forward to returning and am hopeful for future collaboration.
It was a privilege to participate in the lead sessions for
#BostonAF
day two speaking about Ablation and AF progression alongside important talks from
@Phiso_de
S. Willems D. Packer F. Marchilinski
There is a lot of discussion about how to monitor for AF, ( binary recurrence or burden), but less discussion about how monitoring influences these outcomes
Now in print
@CircAHA
we aimed to address this, with a goal of informing trial design & practice
1/
Happy to share that our recent publication on “best practices” with cryoballoon-based pulmonary vein isolation is now available onsite and is open access. The focus is dosing and monitoring. It was a pleasure to collaborate with such a great group.
1/3 Haven’t had time to fully digest the new atrial fibrillation guideline. But I find it surprising that the ACC/AHA/HRS would endorse Apixaban use in dialysis patients.
@hswapnil
@brownpa79
@kidney_boy
Thanks!
It was a surprise and honour to receive this recognition from
@uOttawaMed
I had a great time catching up with old friends at my alma mater last weekend.
🎉Congratulations to
@DrJasonAndrade
(Cardiology) on receiving
@uOttawa
's Rising Star Achievement Award recognizing an outstanding alum who models professional excellence and exceptional leadership while making significant contributions to medicine. Visit:
It’s been a few years since I’ve done cases with
@AbbottCardio
EnSite Precision. Despite my early EP career being NAVx for all mapping cases, i have spent the past 5 years almost exclusively using
@BiosenseWebster
CARTO (except Pediatric cases)
This was my first with the HD Grid
#EPeeps
- Catheter ablation of persistent AF remains a challenge, given the mechanisms sustaining persistent atrial fibrillation remain unclear.
Extra-PVI strategies have not consistently demonstrated benefit beyond PVI alone.
What about drivers from ECGi?
EARLY-AF listed in the NEJM Journal Watch Cardiology Top Stories of 2022
Thanks again to the patients and collaborators for enabling this research program, and being so committed to addressing the question of “best initial treatment for AF”
Just published! - congratulations to Dr. Jason Andrade for his comprehensive update to the bestselling Clinical Cardiac EP Handbook - now available in a new second edition.
@DrJasonAndrade
7. To conclude
PVI performed by contact force RF and cryoballoon are equally efficacious at preventing recurrence and reducing AF burden detected on ILR.
But progression rates differed by ablation energy.
Congrats to
@Elliott_AD
@PrashSanders
@melissaemm1
@DH_Lau
and colleagues on Exercise and Physical Activity Program in Patients With Atrial Fibrillation: The ACTIVE-AF Randomized Controlled Trial - great work!
#EPeeps
- The S-ICD is a major step-forward in device therapy for the prevention of sudden death, however, Inappropriate shocks occur twice as frequently with S-ICD compared to standard transvenous ICD.
One reason is due to change in ECG over follow-up.
We know progression from paroxysmal AF to persistent AF is associated with worse outcomes.
And we know Cryoballoon ablation decreases progression vs AAD therapy.
Join us at ESC for late-breaking science comparing cryoballoon ablation and RF ablation
I feel immensely privileged to have had known Dr Wyse (
@dgwyse
). George was such a caring, kind and wonderful man who, despite his landmark accomplishments, was approachable and humble. And he gave that most precious thing, his time.
Raise a 🍷 to them.
Preparing for
@westernAFib
and came across this quote. Sums up the difficulty with assessing QOL in AF.
“A fugitive illness that only visits a patient periodically may be more difficult to bear than one whose effects are durable and persistent.”—William Evans, 1959.
Massive thanks to:
@atulverma_md
for his guidance and mentorship.
Patricia Theoret-Patrick
@uOttawa
for coordinating the trials.
Li Chen and George Wells for their statistical analysis and methodology.
And all the patient partners at our 18 participating sites across Canada.
The AVANT GUARD clinical trial has commenced and will evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System as a first-line treatment for persistent atrial fibrillation (AF). Learn more:
Our review in
@JACCJournals
discussing ablation as a means to reduce AF burden.
Congratulations to Hannah Schwennesen on leading this review, and many thanks to Kathryn Wood and
@JonPicciniSr
for inviting me to collaborate on this important topic.
Congratulations to
@nmarrouche
and colleagues for undertaking this important trial. Clearly lots to unpack in a trial of this magnitude.
At a minimum it highlights that earlier intervention is better, before the scar has had time to progress to stage 3/4.
#EPeeps
- did a recent redo ablation procedure for atypical flutter.
Attached is the voltage map with Rhythmia.
The clinical arrhythmia ended up being a right free wall atypical flutter, but more concerning is that there was ~no measurable voltage in the LA or posterior RA.
Dr Scherr offering his insightful commentary on the CIRCA-DOSE results. Re-iterating the differences in the definition of “success” after AF ablation depending on which endpoint you use.
53% time to event vs. 99% reduction in burden.
@drjohnm
Now available in
@hrs_journal
(open access) - Trends in Implantable Cardioverter-Defibrillator Programming Practices and its Impact on Therapies: Insights from a North American Remote Monitoring Registry 2007 – 2018
#HRStweetorialtuesday
#EPeeps
- Pacing-induced cardiomyopathy occurs in up to 20% of patients after 3–4 years of RV pacing
It has been primarily attributed to functional LBBB and LV dyssynchrony induced by RV pacing, thus prevention focuses on resynchrony
Do statins offer hope?
#EPeeps
- Poor R wave progression is a common finding on a standard 12-lead ECG, but its physiological background and clinical significance are still not fully understood.
Data from a large health examination survey suggest it may not be benign.
Our article examing the Cost-Effectiveness of First-Line Cryoablation versus First-Line antiarrhythmic drug therapy in the Canadian health care system is now available in
@CJCJournals
Great debate with my friend
@LuigiDiBiaseMD
regarding the optimal ablation strategy for persistent AF.
I’m told the session was so well attended that the room capacity was exceeded.
#HRS2022
@HRSonline
@CHRS_SCR
Important findings in the domain of stroke-prevention for AF. Reaffirms the contemporary definition of non-valvular AF, highlighting that DOACs remain a treatment option in patients with normally functioning bioprosthetic valves. Congratulations to
@RenatoDLopes1
and co-authors.
In a trial comparing rivaroxaban with dose-adjusted warfarin, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months.
#AHA20
#EPeeps
- More data indicating EARLY invasive management of AF is associated with improved outcomes
Similar to our RCT meta-analysis () this propensity-matched analysis of the KiCS-AF multicenter registry from
#Japan
showed ↓ HCU
If we move towards first line Cryoballoon ablation then it obliged us to consider the cost impact of earlier intervention.
Attached below is a U.S. Medicare based analysis examining the cost effectiveness of first line Cryoballoon ablation
@omwazni
Wonderful way to end to
#AFSymposium2021
Congratulations to Jeremy Ruskin,
@MoussaMansour10
, Vivek Reddy and the organisers for putting together such a fantastic program with such a do raw and esteemed faculty.
Can’t wait to do it again in person.